Lenvatinib in Thyroid Cancer With and Without VEGF-Targeted Therapy

Matthew H. Taylor, MD, Oregon Health and Science University, discusses the efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.

Matthew H. Taylor, MD, Oregon Health and Science University, discusses the efficacy and safety of lenvatinib for the treatment of patients with131I